Depo-Provera Lawsuit Case Review
Thousands of women have filed legal claims alleging that the birth control injection Depo-Provera (including Depo-SubQ and generic versions) may increase the chance of developing meningiomas — tumors that form in the brain. The lawsuits argue that Pfizer and other manufacturers failed to warn patients and physicians about these risks. As of July 2025, more than 550 lawsuits have been consolidated into a federal multidistrict litigation (MDL), with more expected as attorneys continue to screen new cases.
Depo-Provera and Brain Tumor Concerns
- A major 2024 study published in the British Medical Journal found that women who used Depo-Provera for a year or more were 5.6× more likely to develop a meningioma.
- Although Europe and the U.K. now require warnings, no similar warning exists on U.S. packaging.
Who May Qualify to File a Depo-Provera Claim?
People may qualify if the following applies:
- You received Depo-Provera or the generic injection.
- You were on the medication for at least 1 year.
- You were later diagnosed with a meningioma or related tumor.
- You are still within your state’s filing deadline (typically 2–3 years after diagnosis).
A case evaluation helps determine eligibility. Speaking with a legal team is the best way to confirm whether your claim qualifies for compensation.
Status of the Depo-Provera Litigation
- Feb 2025: MDL No. 3140 created in the Northern District of Florida.
- July 2025: Over 550 active lawsuits with new claims screened each month.
- Discovery: More than 8,000 documents exchanged between attorneys.
- Next phase: Bellwether trials expected in 2025–2026.
Case Review
Disclaimer: This is attorney advertising. Submitting this form does not create an attorney-client relationship. Legal outcomes vary by case and state. Speak with a licensed attorney for specific advice.